Speculatively, this difference may account for the apparent selection for JAK1 LOF mutations in dMMR EC, and possibly even the partial sensitivity of MMRp ECs to immune checkpoint inhibition [49], in contrast to the refractoriness of MMRp CRC to such therapy. Here, JAK1 is linked to colorectal carcinoma.